Welcome to our dedicated page for Bausch + Lomb Corporation SEC filings (Ticker: BLCO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Bausch + Lomb Corporation (BLCO) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, drawn directly from the EDGAR system. As a Canadian-incorporated issuer with common shares listed on the New York Stock Exchange and the Toronto Stock Exchange, Bausch + Lomb files annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, along with exhibits such as credit agreements, indentures and press releases.
For an eye health company operating in vision care, surgical products and ophthalmic pharmaceuticals, these filings contain detailed information on segment performance, risk factors, capital structure and governance. Recent Form 8-K filings describe material events including secured notes offerings, amendments to the company’s credit and guaranty agreement, creation of new term loan tranches and revolving credit facilities, refinancing of existing borrowings, quarterly financial results, investor day materials and changes in the composition of the board of directors.
Investors can use this page to review Bausch + Lomb’s disclosures on direct financial obligations, covenants, leverage ratios and maturity profiles, as well as governance items such as director appointments, committee assignments and executive compensation arrangements referenced in current reports. Over time, the archive will also include annual 10-K reports and quarterly 10-Q reports, which provide more comprehensive discussions of the company’s business, segments, risk factors and financial statements.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand the nature of new term loans, secured notes, amendments, results of operations and other reported events. Users can also monitor current reports that reference press releases on topics such as investor day presentations, refinancing transactions and quarterly earnings, using this page as a central source for BLCO’s regulatory history and ongoing disclosure record.
EVP of R&D and CMO Yehia Hashad filed a Form 4 for Bausch + Lomb (BLCO). On 07/25/2025 he disposed of 2,841 common shares at an accounting price of $14.32 under transaction code F, indicating shares were withheld solely to cover payroll-tax obligations triggered by the vesting of restricted share units. The disposition was not an open-market sale and does not change the executive’s economic exposure. After the withholding, Hashad directly owns 116,739 BLCO shares. No derivative securities were reported. The filing signals continued sizable insider ownership and appears routine rather than indicative of a change in insider sentiment.
Bausch + Lomb Corporation (BLCO) filed a Form 4 showing EVP & CFO Sam Eldessouky completed an administrative equity transaction on 25-Jul-2025. Exactly 3,996 common shares were withheld by the company (transaction code “F”) at an indicated price of $14.32 to cover tax obligations triggered by the vesting of restricted share units. No open-market buying or selling occurred.
After the tax-settlement, Eldessouky’s direct beneficial ownership stands at 278,299 BLCO shares. The filing lists no derivative security activity and leaves his overall stake largely unchanged. Because the shares were surrendered to the issuer rather than sold to investors, the event is considered routine and is unlikely to influence the stock’s supply-demand dynamics or signal a change in the executive’s outlook.
Bausch + Lomb (NYSE:BLCO) filed an 8-K detailing completion of a €675 million senior secured floating-rate note offering due 2031 and a comprehensive debt refinancing.
The company also executed a Third Amendment to its credit agreement, adding $2.325 billion of term loans maturing 2031 and replacing its $500 million revolver with a new $800 million facility maturing 2030.
Proceeds were used to fully repay the outstanding revolver and refinance all term A and B loans due 2027, effectively pushing major maturities out by four years and increasing available liquidity by $300 million.
The notes bear 3-month EURIBOR + 3.875%; term loans carry SOFR + 4.25% (base-rate +3.25%). The amendment raises the maximum first-lien net leverage covenant to 5.75×, stepping down over time, and retains customary covenants and events of default.